# A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

> **NCT05446142** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Encorafenib capsule formulation (CAP)
- **DRUG:** Encorafenib first formulation
- **DRUG:** Encorafenib second formulation
- **DRUG:** Rabeprazole tablet

## Key facts

- **NCT ID:** NCT05446142
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-02-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05446142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05446142, "A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05446142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*